Broker Notes: Why analysts name TPG, Metcash and Actinogen to buy now?

$Actinogen Medical Ltd (ACW.AU)$: Actinogen gets a speculative buy rating and A$0.09 target price as Bell Potter initiates coverage of the stock.
Australian biotech company following promising initial trial results for its lead cognitive-impairment drug candidate. Actinogen's Xanamem inhibits the enzyme that activates cortisol, high levels of which have been linked to diseases including Alzheimer's and major depression.

$TPG Telecom Ltd (TPG.AU)$: UBS trims the target price by 2.8% to A$6.90 on higher interest-rate assumptions but maintains a buy rating on the stock.
TPG Telecom looks undervalued to UBS analyst Tom Beadle, who continues to believe the market is focused on near-term headwinds rather than long-term upside.

$Metcash Ltd (MTS.AU)$: UBS maintains a buy rating and A$5.00 target price on the stock.
Metcash's FY 2022 results will show hardware sales rising by 16% on-year, UBS analyst Shaun Cousins predicts.

$Cochlear Ltd (COH.AU)$, $Temple & Webster Group Ltd (TPW.AU)$, $ANZ Group Holdings Ltd (ANZ.AU)$, $Appen Ltd (APX.AU)$, $Bank of Queensland Ltd (BOQ.AU)$, $Bendigo and Adelaide Bank Ltd (BEN.AU)$